secwatch.observer — SEC 8-K summary
======================================

Issuer:     Petros Pharmaceuticals, Inc. (PTPI)
CIK:        0001815903
Form:       8-K
Filed at:   2025-01-24T23:59:59+00:00
Accession:  0001104659-25-005980
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Petros Pharmaceuticals amends Series A Preferred; maturity extended to Feb 2025, $500k cash covenant added
--------------------------------------------------------------------------------

- Extended maturity date of Series A Convertible Preferred Stock from prior date to February 15, 2025.
- Deferred all unpaid accrued amounts under the Certificate of Designations to February 15, 2025.
- Company must maintain at least $500,000 in unrestricted cash from January 15 to February 15, 2025.
- Amended restrictive covenant to allow changes in sales strategy for Stendra avanafil and OTC switch platform.
- Required holders waived any breach from failure to pay outstanding amounts as of January 23, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815903/000110465925005980/0001104659-25-005980-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815903/000110465925005980/tm254392d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-005980

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer